Cardiovascular outcome trials have shown considerable improvement in heart failure hospitalisation and other cardiovascular outcomes in people using sodium-glucose co-transporter-2 (SGLT-2) inhibitors.

There are currently no treatments demonstrating mortality benefit for people with heart failure and preserved ejection fraction (HFpEF).

The EMPEROR trials will considerably add to our understanding of the future role for SGLT-2 inhibitors in people with heart failure, particularly HFpEF.

Planned sub-analyses of the EMPEROR trials, which include analyses of changes in renal function and incident diabetes, will also be of particular interest.